Abstract
AbstractNeonatal thyrotoxicosis is mostly caused by the transplacental passage of maternal thyroid stimulating hormone (TSH) receptor antibodies (TRAb) to the fetus. Although rare and transient, this condition may be associated with significant morbidity and mortality if not diagnosed and treated in an appropriate and timely manner. Anti-thyroid drugs are the main therapy. Here, we report a preterm newborn that presented with two uncommon presentations of neonatal thyrotoxicosis, cholestasis and pulmonary hypertension that significantly improved following the administration of anti-thyroid medications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
